My Companies
Notification
Account
Log Out
Login
The US FDA classified Aurobindo Pharma’s subsidiary (Eugia Unit-III) as 'Official Action Indicated' (OAI) following an inspection with 11 observations. This regulatory status signifies serious compliance issues, likely halting new product approvals from the facility and introducing significant operational risk.
Aurobindo Pharma Unit I Receives US FDA Warning Letter
Aurobindo Pharma Gets FTC Approval for Lannett Acquisition, Closing This Month